drug summary · 2 NDC codes
JAKAFI XR 22 mg/1
ruxolitinib
HUMAN PRESCRIPTION DRUG record from the RxAtlas dataset, marketing status NDA. Facts and NDC codes below are exported values from the current release, not inferred or edited prose.
Facts
Field definitions, types, and provenance rules are in the data dictionary.
| generic name | ruxolitinib |
|---|---|
| active ingredients | RUXOLITINIB |
| dosage form | TABLET, EXTENDED RELEASE |
| route | ORAL |
| strength | 22 mg/1 |
| marketing status | NDA |
| DEA schedule | not reported |
| application number | NDA217180 |
| ATC code | not reported |
| RxCUI | not reported |
| manufacturer | Incyte Corporation |
| product type | HUMAN PRESCRIPTION DRUG |
| pharmacologic class | Janus Kinase Inhibitor [EPC]; Janus Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC] |
NDC codes
2 National Drug Codes are mapped to this product in the current release. Package descriptions are not part of the published export, so the NDC code is the canonical package identifier here.
| NDC | Package description |
|---|---|
| 50881-022 | — |
| 50881002208 | — |
Other ruxolitinib products
9 other products in the current release publish the same generic name. Strength, dosage form, and labeler are what distinguish them.
- JAKAFI 10 mg/1TABLET · Incyte Corporation
- JAKAFI XR 11 mg/1TABLET, EXTENDED RELEASE · Incyte Corporation
- JAKAFI 15 mg/1TABLET · Incyte Corporation
- JAKAFI 20 mg/1TABLET · Incyte Corporation
- JAKAFI 25 mg/1TABLET · Incyte Corporation
- JAKAFI XR 33 mg/1TABLET, EXTENDED RELEASE · Incyte Corporation
- JAKAFI XR 44 mg/1TABLET, EXTENDED RELEASE · Incyte Corporation
- JAKAFI 5 mg/1TABLET · Incyte Corporation
- JAKAFI XR 55 mg/1TABLET, EXTENDED RELEASE · Incyte Corporation
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access to the full catalogue; credited toward the licence.